UCB (OTCMKTS:UCBJY) Sees Strong Trading Volume – Still a Buy?
by Jessica Moore · The Cerbat GemUCB SA (OTCMKTS:UCBJY – Get Free Report) shares saw strong trading volume on Tuesday . 106,222 shares changed hands during trading, an increase of 206% from the previous session’s volume of 34,726 shares.The stock last traded at $159.45 and had previously closed at $162.2318.
Analysts Set New Price Targets
Separately, Wolfe Research upgraded UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy”.
Read Our Latest Analysis on UCBJY
UCB Price Performance
The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. The company has a 50 day moving average price of $153.31 and a 200 day moving average price of $145.58.
About UCB
UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.
The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.